Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
Authors:ID Mesti, Tanja (Author)
ID Ebert Moltara, Maja (Author)
ID Boc, Marko (Author)
ID Reberšek, Martina (Author)
ID Ocvirk, Janja (Author)
Files:.pdf PDF - Presentation file, download (534,06 KB)
MD5: 9E8FC7EE5F8AE0DF84FC237948A95CEA
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. Patients and methods. The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospectively reviewed. All patients received bevacizumab (10 mg/kg) and irinotecan (340 mg/m2 or 125 mg/m2) every two weeks. Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated. Results. Between August 2008 and November 2011, 19 patients with recurrent malignant gliomas (median age 44.7, male 73.7%, WHO performance status 0%2) were treated with bevacizumab/irinotecan regimen. Thirteen patients had glioblastoma, 5 anaplastic astrocytoma and 1 anaplastic oligoastrocytoma. With exception of one patient, all patients had initially a standard therapy with primary resection followed by postoperative chemoradiotherapy. Radiological response was confirmed after 3 months in 9 patients (1 complete response, 8 partial responses), seven patients had stable disease and three patients have progressed. The median PFS was 6.8 months (95% confidence interval [CI]: 5.3-8.3) with six-month PFS rate 52.6%. The median OS was 7.7 months (95% CI: 6.6-8.7), while six-month and twelve-month survival rates were 68.4% and 31.6%, respectively. There were 16 cases of hematopoietic toxicity grade (G) 1-2. Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3. No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed. Conclusions. In recurrent malignant gliomas combination of bevacizumab and irinotecan might be an active regimen with acceptable toxicity.
Keywords:recurrent malignant glioma, systemic therapy, bevacizumab
Publication status:Published
Publication version:Version of Record
Publication date:01.03.2015
Publisher:Association of Radiology and Oncology
Year of publishing:2015
Number of pages:str. 80-85, VI
Numbering:Vol. 49, no. 1
Source:Ljubljana
PID:20.500.12556/DiRROS-18723 New window
UDC:616.8-006
ISSN on article:1318-2099
DOI:10.2478/raon-2014-0021 New window
COBISS.SI-ID:1813371 New window
Copyright:by Authors
Publication date in DiRROS:17.04.2024
Views:482
Downloads:176
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Keywords:maligni gliom, bevacizumab, irinotecan, sistemska terapija


Back